20.06.2018 • NewsDede WillamsAzelis

Azelis to be bought by EQT and PSP Funds

Azelis to be bought by EQT and PSP Funds (c) Azelis
Azelis to be bought by EQT and PSP Funds (c) Azelis

Antwerp, Belgium-based specialty chemicals and food ingredients distributor Azelis said its private equity owner Apax Partners has received a binding takeover offer from two other funds, EQT VIII and PSP Investments, and is in exclusive negotiations to transfer its holding.

The transaction, for which financial terms were not disclosed, is subject to regulatory approvals, and other conditions including consultation with employee representatives. A closing is targeted for the fourth quarter of 2018.

Established in 2001, Azelis, which fields a high-end technical sales force, supplies a diverse range of products and services to more than 43,000 customers in over 40 countries. The distributor also operates more than 50 of its own application laboratories.

Private equity investor 3i acquired a majority stake in Azelis in 2007. Since its acquisition by Apax in 2015, the distributor said it has successfully executed its targeted growth strategy through focusing the business on product development and innovation, as well as developing its M&A platform.

Over past three years, the company has more than doubled sales revenue and tripled EBITDA while at the same time making nine acquisitions to broaden its geographic reach and product offering.

By its own account, Azelis’ most significant deal to date was the 2015 takeover of Koda Distribution Group, whose North American presence was complementary to its own  European and Asian reach. This, it said, expanded the company into a “truly global player.”

In 2016, Azelis acquired 100% of Milan-based distribuor Ametech and in 2017 alone picked up four more companies, including US distributor Ross Organic, Denmark’s LCH, Chemcolour, based in Australia and New Zealand and Georges Walther, a family-owned specialty chemicals distributor. So far in 2017, it has bought South Korea’s Sammi Chem and taken full ownership of Distralim, a Moroccan distributor of food ingredients.

Going forward, the distributor said its strategy is to continue to leverage its diversified business model.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.

Photo
21.03.2025 • News

What’s Next for Pharma Supply Chains?

Sudden shifts in demand, supply shortages and global collapse have put immense pressure on pharmaceutical logistics. To address these challenges, PHARMAP 2025 brings together industry experts to discover AI-driven supply chain optimisation, strategic logistics partnerships and digital solutions that enhance efficiency and resilience in the pharmaceutical supply chain.

Photo
24.04.2025 • NewsBioprocessing

Fujifilm Diosynth Biotechnologies & Regeneron Sign Manufacturing Agreement

Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today announced a 10-year manufacturing supply agreement, valued at over $3 billion (€2.64 billion), with Regeneron Pharmaceuticals to provide US-based production of its industry-leading biologic medicines, which treat millions of patients worldwide.